May 20, 2025
StemRIM Inc.

StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders (including Traumatic Cartilage Defect, Osteoarthritis, and Osteochondritis dissecans)

Osaka, Japan, May 20, 2025 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; “StemRIM”) announces that a patent will soon be registered in Europe for the application related to the novel treatment of cartilage disorders (including traumatic cartilage defect, osteoarthritis, and osteochondritis dissecans) utilizing the peptide drug developed from the “Regeneration-Inducing Medicine™" development candidate Redasemtide (HMGB1 fragment peptide).

Title of Invention	:	HMGB1 derived peptide for treating or preventing a cartilage disorder (Originally filed as: Therapeutic medication for cartilage disorder)
Region	:	Europe
Application No.	:	19875071.3
Registration No.	:	To be determined
Applicant	:	StemRIM, Osaka University

This patent is intended to expand the indications for Redasemtide, which is currently under development, and we believe that the granting of this patent will ensure the possibility of developing a drug for cartilage disorders (including traumatic cartilage defect, osteoarthritis, and osteochondritis dissecans) in Europe.

The 5 major European countries—Germany, France, the United Kingdom, Italy, and Spain—collectively represent the world’s second-largest pharmaceutical market after the US, accounting for approximately 14.1% of the global market in 2023. As in Japan, these countries are experiencing demographic shifts marked by declining birth rates and aging populations, which in turn are driving increasingly diverse and sophisticated medical needs. Against this backdrop, continued growth of the pharmaceutical sector is anticipated. Within such a landscape, our "Regeneration-Inducing Medicine™", Redasemtide, administered via intravenous injection—a patient-friendly mode of delivery—holds significant promise as a valuable therapeutic option in future clinical practice. It is expected to serve as a key pillar in enhancing our presence in the European market.

The impact on the financial performance for the fiscal year ending July 31, 2025, is insignificant. We will promptly disclose any additional information that needs to be disclosed.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with ectomesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
X: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)